Live Analytics
Comments 0
Sputnik V peer reviewed Analytics Table
Income Estimates for Sputnik V peer reviewed
Based on this YouTube video's total view count of 240K views and industry-standard rates, the estimated total earning is $168 - $481 through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.
About Sputnik V peer reviewed
Explore Sputnik V peer reviewed with 240,535 views, 7,895 likes, and 2,862 comments. Experience the impact of this video content that has captured audience attention.
Sputnik V (Gam-Covid-Vac) 2 doses, 3 weeks apart Muscle injection Freezer storage Developing an alternative formulation that can be refrigerated Gamaleya Research Institute (Ministry of Health) Combination of two adenoviruses called Ad5 and Ad26 August 11th President Putin announced approval Before phase 3 trials had started November, Russian government began offering Sputnik V within Russia Widespread hesitancy Phase 3, Russia, Belarus, UAE, Venezuela, India Gamaleya Institute joined forces in December with the AstraZeneca AstraZeneca / Gamaleya combination started Phase 1 trial on Dec. 24 Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00234-8/fulltext Background A heterologous recombinant adenovirus Phase 2 results, showed a good safety profile and induced strong humoral and cellular immune responses Interim analysis of this phase 3 trial Methods Randomised, double-blind, placebo-controlled, phase 3 trial 25 hospitals and polyclinics in Moscow Participants at least 18 years, with negative PCR and IgG and IgM tests Randomly assigned (3:1) to receive vaccine or placebo Two shots, 21 days apart First dose, rAd26 Second dose, rAd5), Both vectors carrying the gene for the full-length SARS-CoV-2 glycoprotein S Outcome recorded 21 days after second shot (vaccine or placebo) Finding Sept 7 to Nov 24, 2020 N = 21 977 Randomly assigned Vaccine group, n = 16 501 Placebo group, n = 5476 N = 19 866 received two doses of vaccine or placebo and were included (2,144 participants older than 60 years, 1,611 in the vaccine group and 533 in the placebo group) Primary outcome analysis Included all participants who had received at least two doses at the time of database lock Vaccine group, n = 14,964 16 (0·1%) confirmed COVID infections No cases of moderate or severe COVID-19 confirmed at least 21 days after dose 1 Placebo group, n = 4,902 62 (1·3%) confirmed COVID infections 20 cases of moderate or severe COVID-19 confirmed at least 21 days after dose 1 Efficacy 91·6% Vaccine efficacy was 91·8 in participants older than 60 years Interim immunogenicity Vaccine group RBD-specific IgG detected in 336 (98%) of 342 samples Seroconversion rate of 98·25% Higher levels of interferon-gamma (secreted by activated T helper lymphocytes, T cytotoxic lymphocytes, B lymphocytes and NKs) Significantly higher levels of IFN-γ secretion upon antigen restimulation Placebo group RBD-specific IgG was detected in 17 (15%) of 114 samples Seroconversion rate of 14·91% (p less than 0·0001 vs the vaccine group) Adverse events Grade 1 7485 [94·0%] of 7966 total events Serous adverse events Vaccine group 45 (0·3%) of 16, 427 Placebo group 23 (0·4%) of 5435 None were considered associated with vaccination Four deaths were reported during the study Vaccine group Three (less than 0·1%) of 16 427 Placebo group One (less than 0·1%) of 5435 None of which were considered related to the vaccine Interpretation This interim analysis of the phase 3 trial of Gam-COVID-Vac showed 91·6% efficacy against COVID-19 and was well tolerated in a large cohort
About YouTube Real-Time View Count
With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.
Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.
Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.
Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.
Embed Widget
Parameters:
fullscreen=true- Fullscreen countergraph=true- Live graph chartcounter=0/1/2- Select counter (0=likes, 1=views, 2=comments)
URL
Click to copy the embed URL to your clipboard

